Generex inks deal With Sanofi-Aventis for insulin supply

WORCESTER, Mass. Sanofi-Aventis’ German subsidiary will supply its insulin to U.S. drug maker Generex Biotechnology Corp. for use in Generex’s insulin spray.

Generex, which specializes in drug delivery for metabolic diseases through the inner lining of the mouth, announced the deal, with Sanofi-Aventis Deutschland GmbH. Under the long-term agreement, Generex will manufacture its buccal insulin spray Oral-lyn using Sanofi’s recombinant human insulin crystals. Financial terms were not disclosed.

“We are very pleased to have entered into this long-term supply agreement for insulin crystal,” Generex president and CEO Anna Gluskin stated. “It solidifies one of our key product components, which will assist in the smooth transition into commercialization of our flagship product, Generex Oral-lyn, into major markets where we will seek to establish a new paradigm for the treatment of diabetes.”